Although the mammalian target of rapamycin (mTOR) inhibitor everolimus and multi-targeted kinase inhibitor sunitinib has been approved for locally advanced and metastatic pancreatic NENs in clinical practice (43), the effect of its application in colorectal neuroendocrine tumors still needs to be observed (44). Here, MTOR is linked to colorectal neuroendocrine tumor.